Posts in category Healthcare


Atossa Genetics (ATOS) Stock Plunges After Reverse Stock Split Announced

A wave of reverse stock splits appears almost inevitable, as battered stocks try to maintain …

GW Pharmaceuticals (GWPH): Epidiolex Will Be Approved Much Before the PDUFA Date, Bets Cantor

Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.

vTv Therapeutics (VTVT) Stock: Healthcare Analysts Move to the Sidelines

Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development …

GW Pharmaceuticals (GWPH) Lead Drug’s Green Light Just Around the Corner? Cowen Joins the Conversation

On back of yesterday’s positive briefing documents, Cowen’s Phil Nadeau roots for FDA approval.

Bristol Myers Squibb (BMY) Will Face Significant Headwinds in 2019; Here’s Why

Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small …

Biotech Talk: Cowen Shares Thoughts on Dynavax (DVAX) Following Favorable Data in Advanced Head and Neck Cancer

Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.

J.P. Morgan Shares Two Cents on Dynavax Technologies’ (DVAX) AACR Update

J.P. Morgan analyst Anupam Rama is out today with a brief research note on shares of Dynavax …

Oppenheimer Cuts Sales Expectations for Synergy Pharmaceuticals (SGYP) Approaching 1Q18 Print; But Better Sales Growth Ahead?

Oppenheimer’s Christopher Liu thinks the Street is too confident on SGYP ahead of its first earnings show of the year- opting for now to stick to the sidelines.

BTIG More Positive on Vericel (VCEL) Product Portfolio Following Analyst and Investor Event

BTIG’s Ryan Zimmerman shares his key takeaways from VCEL’s Analyst Day- with a confident verdict.

TherapeuticsMD’s (TXMD) TX-004 Takes a Step Forward to FDA Approval, Says Cantor

TherapeuticsMD (NASDAQ:TXMD) investors have a smile on their faces Wednesday, after the drug maker disclosed that …